dr. kuykendall on toxicity profiles of ruxolitinib and fedratinib in myelofibrosis
Published 4 years ago • 165 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
1:27
dr. kuykendall on choosing ruxolitinib or fedratinib in myelofibrosis
-
1:12
dr. kuykendall on the approval of fedratinib in myelofibrosis
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
0:45
exploring fda-approved treatment options for patients with myelofibrosis
-
2:22
dr. scherber discusses ruxolitinib failure in myelofibrosis
-
1:10
fedratinib reemerges as fda-approved treatment of myelofibrosis
-
1:40
fedratinib compared to ruxolitinib in the frontline setting for treatment of myelofibrosis
-
0:50
dr. snyder on how ruxolitinib and fedratinib may pave the way to transplant in myelofibrosis
-
0:56
dr. saint fleur-lominy on the use of ruxolitinib versus fedratinib in mpns
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:10
dr. bradley on the utility of ruxolitinib in myelofibrosis and polycythemia vera
-
3:09
key data for the use of fedratinib in mf
-
1:06
fedratinib: mpn-associated myelofibrosis
-
4:46
fedratinib for primary myelofibrosis
-
4:42
response-2 trial: ruxolitinib for pv
-
2:07
fedratinib for myelofibrosis
-
5:30
managing treatment-related toxicities with jak inhibitor therapy in myelofibrosis
-
2:55
novel combinations with ruxolitinib being investigated for myelofibrosis
-
5:10
fedratinib in mf: jakarta2 and freedom trials